Completed
Study of Adalimumab (HUMIRA®) in Patients With Moderate to Severe Psoriasis (PS) in Spain (PROMISE)
NCT01076192
- Conditions
- Moderate-to-severe Chronic Plaque Psoriasis, Psoriasis, Skin Diseases, +2 more
- Locations
-
Not specified